Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for rare diseases.

[1] Decuprate has been granted orphan drug designation for the treatment of Wilson's disease in both Europe and the United States.

[2] Wilson Therapeutics presented during the 10th Kempen & Co Life Sciences Conference 2017 and showed the world the result with the drug Decuprate.

[citation needed] As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology[3][4][5][6][7][8][9][10][11][12] and Wilson's disease,[13][14][15][16] as well as some other clinical pathologies.

[17][18] Wilson Therapeutics was founded in 2012 by HealthCap, one of the leading European life science venture capital funds.